Premium
Experience with a third generation recombinant factor VIII concentrate (Advate ® ) for immune tolerance induction in patients with haemophilia A
Author(s) -
VALENTINO L. A.,
RECHT M.,
DIPAOLA J.,
SHAPIRO A. D.,
PIPE S. W.,
EWING N.,
URGO J.,
BULLOCK T.,
SIMMONS M.,
DEGUZMAN C.
Publication year - 2009
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2008.01960.x
Subject(s) - medicine , haemophilia , haemophilia a , adverse effect , immune tolerance , immune system , incidence (geometry) , recombinant dna , titer , immunology , pediatrics , antibody , biochemistry , chemistry , physics , optics , gene
Summary. The development of an inhibitor represents one of the most challenging complications in patients with haemophilia A. Optimal management is immune tolerance induction (ITI), typically through the administration of high doses of factor VIII (FVIII) concentrate. Among 12 patients who underwent ITI using Advate, a third‐generation recombinant FVIII product that is free of animal and human protein additives, tolerance was achieved in nine (75%), including seven of 10 patients (70%) with high‐titre inhibitors. ITI is ongoing in two patients and not yet successful; immune tolerance failed in the third patient. The median time to success was 4.0 months for group as a whole and for patients with high‐titre inhibitors. Treatment was well tolerated, and no adverse events were observed. Advate was found to be equivalent to other FVIII products with regard to both ITI success rates and the incidence of adverse effects when used in these immune tolerance regimens.